NCT07449754 2026-03-04
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
Hanmi Pharmaceutical Company Limited
Phase 2 Recruiting
Clinical Trials
29 trialsNCT02721459 2026-03-02
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT04835805 2026-02-03
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
Genentech, Inc.
Phase 1 Active not recruiting
NCT04109456 2026-01-15
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
InxMed (Shanghai) Co., Ltd.
Phase 1 Completed
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT03175432 2025-11-03
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02908672 2025-07-20
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
Hoffmann-La Roche
Phase 3 Completed
NCT02902029 2025-04-09
ImmunoCobiVem
University Hospital, Essen
Phase 2 Completed
NCT04722575 2025-03-13
NEO-TIM
Fondazione Melanoma Onlus
Phase 2 Active not recruiting
NCT03101254 2024-07-17
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT04190628 2024-05-21
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
ABM Therapeutics Corporation
Phase 1 Terminated
NCT03625141 2024-04-11
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
Hoffmann-La Roche
Phase 2 Completed
NCT05756556 2024-02-01
T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma
ImmVira Pharma Co. Ltd
Phase 2 Suspended
NCT03430947 2023-09-14
RadioCoBRIM
Technische Universität Dresden
Phase 2 Terminated
NCT03989115 2023-06-26
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Phase 1/2 Completed
NCT02414750 2022-11-30
REPOSIT
Netherlands Working Group on Immunotherapy of Oncology
Phase 2 Terminated
NCT02036086 2022-10-27
Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Sunnybrook Health Sciences Centre
Phase 2 Unknown
NCT01689519 2022-05-02
coBRIM
Hoffmann-La Roche
Phase 3 Completed
NCT02818023 2022-01-03
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
University of Pittsburgh
Phase 1 Terminated
NCT03224208 2021-04-26
VECODUE
Fondazione Melanoma Onlus
Phase 2 Terminated
NCT02303951 2021-02-03
NEO-VC
University Hospital Tuebingen
Phase 2 Terminated
NCT01656642 2020-07-21
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
Genentech, Inc.
Phase 1 Completed
NCT02537600 2020-01-27
CONVERCE
Center Eugene Marquis
Phase 2 Completed
NCT02768207 2019-08-28
A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma
Hoffmann-La Roche
Phase 2 Completed
NCT01271803 2019-07-29
A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
Hoffmann-La Roche
Phase 1 Completed
NCT01813214 2019-02-26
The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
Georgetown University
Phase 2 Terminated
NCT02457793 2018-11-20
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01495988 2017-10-24
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Melanoma Research Foundation Breakthrough Consortium
Phase 2 Terminated
NCT02427893 2016-11-15
Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 3 Withdrawn